Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Endari Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Endari (glutamine) Prior Authorization Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization approval and renewal for Endari (glutamine) 5-gram powder packets for sickle cell disease under the Boeing commercial formulary. It applies to providers requesting initial or continuation therapy.

    Policy Summary
    PayerPrime Therapeutics
    PolicyEndari (glutamine) Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing sickle cell disease, qualifying hydroxyurea history or exception, and a dose within FDA labeling for initial Endari approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    5 GMEndari strength
    Sickle cell diseaseCovered indication
    6 monthsHydroxyurea trial
    Clinical benefit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Renewal requirement

    Coverage Criteria

    Initial Therapy

    Approval requires ALL of the following criteria to be met.

    • Disease and use: The patient has a diagnosis of sickle cell disease and is using the requested agent to reduce the acute complications of sickle cell disease.
    • Age support when an FDA-approved indication applies

      • FDA-labeled age: The patient's age is within FDA labeling for the requested indication.
      • Supported age use: There is support for using the requested agent for the patient's age for the requested indication.
    • Hydroxyurea history or exception

      • Inadequate response: The patient tried and had an inadequate response to maximally tolerated hydroxyurea after at least 6 months of therapy.at least 6 months

        Chart notes are required.

      • Intolerance or hypersensitivity: The patient has an intolerance or hypersensitivity to hydroxyurea.
      • Contraindication: The patient has an FDA-labeled contraindication to hydroxyurea.
    • Adakveo combination

      • No combination use: The patient will not use the requested agent in combination with Adakveo (crizanlizumab-tmca).
      • Supported combination use: There is support for use of the requested agent in combination with Adakveo (crizanlizumab-tmca).
    • Brand over generic, when applicable

      • Generic intolerance or hypersensitivity: The patient has an intolerance or hypersensitivity to the generic equivalent that is not expected to occur with the requested brand agent.
      • Generic contraindication: The patient has an FDA-labeled contraindication to the generic equivalent that is not expected to occur with the requested brand agent.
      • Brand rationale: There is support for use of the requested brand agent over the generic equivalent.
    • Safety and quantity: The patient does not have any FDA-labeled contraindications to the requested agent, and the requested quantity or dose is within FDA labeling for the requested indication.Within FDA labeling

    Continuation Therapy

    Approval requires ALL of the following criteria to be met.

    • Prior approval and clinical benefit: The patient has been previously approved for the requested agent through the plan's prior authorization process and has had clinical benefit with the requested agent.

      Patients not previously approved require initial evaluation review.

    • Adakveo combination

      • No combination use: The patient will not use the requested agent in combination with Adakveo (crizanlizumab-tmca).
      • Supported combination use: There is support for use of the requested agent in combination with Adakveo (crizanlizumab-tmca).
    • Brand over generic, when applicable

    Approval is excluded when the patient has an FDA-labeled contraindication to the requested agent. The requested dose or quantity must also remain within FDA labeling for the requested indication.

    Prior Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Submit an initial prior authorization request for Endari (L-glutamine) for a patient with sickle cell disease who will use the drug to reduce acute complications. Initial approval requires all applicable clinical, step-therapy, combination-use, brand-over-generic, contraindication, and dose requirements below.

    • Initial review applies to patients not previously approved through the plan's prior authorization process.
    • Document the diagnosis, intended indication, and all required clinical rationale in the request.
    Prior Authorization

    Renewal Prior Authorization Requirements

    For renewal, document that the patient was previously approved for Endari through the plan's prior authorization process and has experienced clinical benefit. Patients without prior plan approval require initial evaluation review.

    • Renewal approval requires both prior plan approval and documented clinical benefit.
    • Continue to address combination-use, brand-over-generic, contraindication, and dose requirements.

    Policy Background

    Endari is glutamine (sickle cell) powder packets, available at a strength of 5 GM. It is used to reduce acute complications of sickle cell disease; initial treatment requires a qualifying hydroxyurea history or exception, while continuation requires demonstrated clinical benefit.

    Drug Definitions

    Endari
    Brand agentEndari
    Product descriptionGlutamine (sickle cell) powder packets
    Strength5 GM
    Generic equivalent
    Generic equivalentL-glutamine
    Brand productEndari
    Policy relevanceBrand Endari requests may require support for use of the brand over L-glutamine

    Endari Initial Therapy

    Endari Initial Therapy

    Initial approval of Endari requires ALL of the following criteria to be met.

    • Disease and use: The patient has a diagnosis of sickle cell disease and is using Endari to reduce the acute complications of sickle cell disease.
    • Age support when an FDA-approved indication applies

      • FDA-labeled age: The patient's age is within FDA labeling for the requested indication for Endari.
      • Supported age use: There is support for using Endari for the patient's age for the requested indication.
    • Hydroxyurea history or exception

    Endari Renewal

    Endari Renewal

    Renewal approval requires ALL of the following criteria to be met.

    • Prior approval and clinical benefit: The patient has been previously approved for Endari through the plan's prior authorization process and has had clinical benefit with Endari.

      Patients not previously approved require initial evaluation review.

    • Adakveo combination

      • No combination use: The patient will not use Endari in combination with Adakveo (crizanlizumab-tmca).
      • Supported combination use: There is support for use of Endari in combination with Adakveo (crizanlizumab-tmca).

    Required Hydroxyurea Trial

    StepRequirementExceptions
    1Try maximally tolerated hydroxyurea before initial Endari approval; an inadequate-response pathway requires at least 6 months of therapy.The hydroxyurea requirement is met if the patient has hydroxyurea intolerance or hypersensitivity, or an FDA-labeled contraindication to hydroxyurea.

    Dose and Quantity Limits

    Quantity limits
    Applies toEndari (glutamine; L-glutamine)
    Quantity requirementThe requested quantity or dose must be within FDA labeling for the requested indication
    Review stagesRequired for both initial approval and renewal
    Policy Summary
    PayerPrime Therapeutics
    PolicyEndari (glutamine) Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing sickle cell disease, qualifying hydroxyurea history or exception, and a dose within FDA labeling for initial Endari approval.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and Provider RequirementsPolicy BackgroundDrug DefinitionsEndari Initial TherapyEndari RenewalRequired Hydroxyurea TrialDose and Quantity Limits
  1. Generic intolerance or hypersensitivity: The patient has an intolerance or hypersensitivity to the generic equivalent that is not expected to occur with the requested brand agent.
  2. Generic contraindication: The patient has an FDA-labeled contraindication to the generic equivalent that is not expected to occur with the requested brand agent.
  3. Brand rationale: There is support for use of the requested brand agent over the generic equivalent.
  4. Safety and quantity: The patient does not have any FDA-labeled contraindications to the requested agent, and the requested quantity or dose is within FDA labeling for the requested indication.Within FDA labeling
  5. Step Therapy

    Hydroxyurea Prerequisite

    Before initial approval, the patient must have tried maximally tolerated hydroxyurea for at least 6 months and had an inadequate response, unless the patient has hydroxyurea intolerance, hypersensitivity, or an FDA-labeled contraindication.

    • The hydroxyurea trial must be at the maximally tolerated dose.
    • An inadequate response after at least 6 months is required when the trial pathway is used.
    • Hydroxyurea intolerance, hypersensitivity, or an FDA-labeled contraindication may satisfy the alternative pathway.
    Documentation Required

    Document the Hydroxyurea Trial

    Include chart notes documenting the maximally tolerated hydroxyurea trial, at least 6 months of therapy, and the patient's inadequate response. If relying on an alternative pathway, document the hydroxyurea intolerance, hypersensitivity, or FDA-labeled contraindication.

    • Chart notes are required for inadequate response to hydroxyurea.
    • Documentation should identify treatment duration, tolerated dose, response, and the reason the response was inadequate.
    Documentation Required

    Clinical Rationale and Dosing Support

    Support the requested use with the patient's sickle cell disease diagnosis and the goal of reducing acute complications. For an FDA-approved indication, document that the patient's age is within FDA labeling or provide support for use at the patient's age. Also document hydroxyurea intolerance or contraindication when applicable, any planned Adakveo combination use, and that the requested dose and quantity are within FDA labeling.

    • Endari must be used for sickle cell disease and to reduce acute complications of the disease.
    • If used with Adakveo (crizanlizumab-tmca), provide support for the combination; otherwise state that the agents will not be combined.
    • The requested dose or quantity must be within FDA labeling for the requested indication.
    Documentation Required

    Renewal Documentation

    For renewal requests, provide current documentation of clinical benefit with Endari and identify the prior approval through the plan's prior authorization process.

    • Clinical benefit must be documented for continued therapy.
    • Patients lacking prior plan approval must undergo initial evaluation review.
    Denial Risk

    Denial Risk: Indication or Age Criteria Not Met

    Do not approve the request when the patient does not have sickle cell disease, the requested use is not to reduce acute complications of sickle cell disease, or the applicable age requirement is not met.

    • For an FDA-approved indication, the patient's age must be within FDA labeling unless there is support for use at that age.
    • The diagnosis and requested indication must be documented.
    Denial Risk

    Denial Risk: Hydroxyurea Requirement Not Met

    Do not approve initial therapy when the patient has not completed the required maximally tolerated hydroxyurea trial with inadequate response after at least 6 months and there is no documented hydroxyurea intolerance, hypersensitivity, or FDA-labeled contraindication.

    • Missing chart-note documentation may prevent approval of the inadequate-response pathway.
    • The hydroxyurea requirement is not met when the trial duration, maximally tolerated dose, or inadequate response is not documented.
    Denial Risk

    Support Combination Therapy with Adakveo

    When Endari will be used with Adakveo (crizanlizumab-tmca), provide supporting evidence for the combination. If no support is supplied, the combination-use requirement is not met.

    • Alternatively, document that Endari will not be used in combination with Adakveo.
    • The same combination-use requirement applies at initial approval and renewal.
    Denial Risk

    Brand-over-Generic Rationale Required

    For brand Endari when generic L-glutamine is available, provide documentation supporting use of the brand over the generic. Acceptable support includes an intolerance or hypersensitivity to L-glutamine not expected with Endari, an FDA-labeled contraindication to L-glutamine not expected with Endari, or other clinical support for brand use.

    • Endari's generic equivalent is L-glutamine.
    • The rationale must explain why the brand is appropriate over the available generic equivalent.
    Denial Risk

    Contraindication and Dose Limits

    Exclude FDA-labeled contraindications to Endari and confirm that the requested dose and quantity are within FDA labeling for the requested indication before submitting or approving the request.

    • Approval is not supported when an FDA-labeled contraindication to Endari is present.
    • Dose or quantity outside FDA labeling may result in denial.
    Denial Risk

    Denial Risk: Renewal Requirements Not Met

    Deny renewal when the patient was not previously approved for Endari through the plan's prior authorization process or when clinical benefit has not been documented.

    • Patients without prior approval require initial evaluation review rather than renewal review.
    • Lack of documented clinical benefit does not satisfy the renewal criteria.
    Adakveo
    Brand nameAdakveo
    Active ingredientCrizanlizumab-tmca
    Combination useUse of the requested agent with Adakveo requires support for combination therapy
    • Inadequate response: The patient tried and had an inadequate response to maximally tolerated hydroxyurea after at least 6 months of therapy.At least 6 months

      Chart notes are required.

    • Intolerance or hypersensitivity: The patient has an intolerance or hypersensitivity to hydroxyurea.
    • Contraindication: The patient has an FDA-labeled contraindication to hydroxyurea.
  6. Adakveo combination

    • No combination use: The patient will not use Endari in combination with Adakveo (crizanlizumab-tmca).
    • Supported combination use: There is support for use of Endari in combination with Adakveo (crizanlizumab-tmca).
  7. Brand over generic, when applicable

    • Generic intolerance or hypersensitivity: The patient has an intolerance or hypersensitivity to L-glutamine that is not expected to occur with Endari.
    • Generic contraindication: The patient has an FDA-labeled contraindication to L-glutamine that is not expected to occur with Endari.
    • Brand rationale: There is support for use of Endari over the generic equivalent, L-glutamine.
  8. Safety and quantity: The patient does not have any FDA-labeled contraindications to Endari, and the requested quantity or dose is within FDA labeling for the requested indication.Within FDA labeling
  9. Brand over generic, when applicable

    • Generic intolerance or hypersensitivity: The patient has an intolerance or hypersensitivity to L-glutamine that is not expected to occur with Endari.
    • Generic contraindication: The patient has an FDA-labeled contraindication to L-glutamine that is not expected to occur with Endari.
    • Brand rationale: There is support for use of Endari over the generic equivalent, L-glutamine.
  10. Safety and quantity: The patient does not have any FDA-labeled contraindications to Endari, and the requested quantity or dose is within FDA labeling for the requested indication.Within FDA labeling